# Pan-Malaria Transmission-Blocking Vaccine AnAPN1

> **NCT05905432** · PHASE1 · COMPLETED · sponsor: **Centre de Recherche Médicale de Lambaréné** · enrollment: 33 (actual)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** Vaccine AnAPN1

## Key facts

- **NCT ID:** NCT05905432
- **Lead sponsor:** Centre de Recherche Médicale de Lambaréné
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-11
- **Primary completion:** 2025-01-22
- **Final completion:** 2025-01-31
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2025-05-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05905432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05905432, "Pan-Malaria Transmission-Blocking Vaccine AnAPN1". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05905432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*